

*Press release*

## **RIEMSER Pharma appoints Dr. Thomas Werner to its Advisory Board**

RIEMSER / BERLIN – December 15, 2014

**RIEMSER Pharma GmbH has appointed Dr. Thomas Werner (58) to its Advisory Board. The former head of GlaxoSmithKline and Bristol-Myers Squibb Germany will primarily support RIEMSER in the further development of its international expansion strategy.**

"We are very proud to have Dr. Thomas Werner on board. His vision and expertise in the pharmaceutical industry will help us to identify new products for our portfolio as part of our growth strategy and open new key markets. The appointment of Thomas Werner represents another step towards establishing RIEMSER Pharma as a leading specialty pharmaceutical company in Europe", explains associate professor Dr. Kai Deusch, CEO of RIEMSER Pharma.

"RIEMSER Pharma is an exceptionally promising company, which has already done an excellent job of positioning itself in the dynamic market of specialty pharmaceutical companies. I am looking forward to promoting RIEMSER Pharma's continued growth together with the management team by providing new impetus for strategic product and company acquisitions", says Dr. Thomas Werner.

Dr. Werner was born in Bremen in 1956 and studied chemistry in Göttingen, where he also received his doctorate. He worked at Bristol-Myers Squibb from 1983 to 1997, at last as Managing Director in Germany. From 1997 to 2009, Dr. Werner served as CEO of GlaxoSmithKline Germany and Central Europe. Since 2009, he has worked as an independent consultant and a member of supervisory and advisory boards of numerous companies in the international pharmaceutical industry.





### **About RIEMSER Pharma GmbH**

RIEMSER Pharma GmbH is a growing European and globally active specialty pharmaceuticals company, which markets, sells and distributes medicinal products for human use in selected therapeutic areas with high unmet medical needs. As part of its strategic growth plan, RIEMSER is currently expanding its market position in European key markets, focusing on accelerating growth in selected areas with high medical needs. RIEMSER has a strong product pipeline and generates lasting value by way of strategic product purchasing and company acquisition coupled with sophisticated life cycle management. RIEMSER has established itself as a modern European platform for the marketing and sales of specialty pharmaceuticals and is an ideal partner for innovative pharmaceutical companies entering new markets for their specialty pharmaceutical products, or intending to extend the life cycles and profitability of their products.

As a responsible company in the pharmaceutical industry, RIEMSER contributes to various medical networks. Among others, these include the association Arzneimittel und Kooperation im Gesundheitswesen (Medicinal Products and Cooperation in the Health Sector), the Bundesverband der Pharmazeutischen Industrie (German Pharmaceutical Industry Association) and the Deutsche Krebsgesellschaft (German Cancer Society).

### **Press contact**

RIEMSER Pharma GmbH  
Claudia Kerber  
Director of Communication  
Tel.: +49 30 338427-477  
Fax: +49 38351 76-48  
E-Mail: [kerber@RIEMSER.com](mailto:kerber@RIEMSER.com)  
[www.RIEMSER.com](http://www.RIEMSER.com)

IRA WÜLFING KOMMUNIKATION GmbH  
Dr. Reinhard Saller  
Tel: +49 89 2000 30-38  
E-Mail: [reinhard.saller@wuelfing-kommunikation.de](mailto:reinhard.saller@wuelfing-kommunikation.de)  
[www.wuelfing-kommunikation.de](http://www.wuelfing-kommunikation.de)